Innovative Technologies and Assays in Support of HIV Cure Research (ITAS-Cure)(R41/R42)
| Jurisdiction: | Federal |
| Incentive Type: | Grant Program |
| Industries: | Medical, Technology, Health And Safety |
| Eligible Sector: | Business |
| Category: | Financial Incentive |
| Time Period: | FY 2015 |
| Governing Body: | National Institutes of Health |
| What’s it worth?: | Not mentioned |
The Innovative Technologies and Assays in Support of HIV Cure Research program support the funding of the implementation of investigator-initiated clinical trials. The program prioritizes high-risk clinical trial proposals to gain a better understanding of clinical mechanisms of infectious, immunologic, and allergic diseases or to improve prevention, diagnosis, and treatment. Funds may be used for the following:
- Training of study personnel
- Enrollment and recruitment of study subjects
- Investigational product cost
- Data collection, management, and quality control
- Laboratory work and data analysis
- Study management and oversight
- Establishment of committees to manage the complexity of the trial
- Preparation of the final study report
- Other pre-approved activities
Typical award amounts of not more than $225,000 for Phase I projects and up to $1,500,000 for Phase II projects with project duration of up to three years. All applicants must meet the following criteria.
